Bulletin of the World Health Organization

Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis

Dan Chisholm, Oye Gureje, Sandra Saldivia, Marcelo Villalón Calderón, Rajitha Wickremasinghe, Nalaka Mendis, Jose-Luis Ayuso-Mateos, Shekhar Saxena

Volume 86, Number 7, July 2008, 542-551

Table 2. Schizophrenia treatment effect size estimates

Intervention scenario Effect size (ES)
Source Disability weight (0 = no disability)
Comparator Value(SD improvement) (Conversion =ES * 0.181)a % improvementover null
Null (no treatment) 22 0.627
Placebo No treatment 0.050 3 0.618 −1%
Older antipsychotic drug Placebo 0.465 32 0.534 −15%
Newer antipsychotic drug Placebo 0.495 32 0.528 −16%
Older antipsychotic drug + psychosocial intervention Older antipsychoticdrug 0.390 31 0.463 −26%
Newer antipsychotic drug + psychosocial intervention Older antipsychoticdrug 0.390 31 0.458 −27%

DALY, disability-adjusted life year; ES, effect size; SD, standard deviation.a Andrews et al.29 obtained health state preference scores/utility values for a series of health states reflecting 1 SD improvement over placebo. The mean change on disability weight associated with 1 SD change in clinical improvement for schizophrenia was 0.181.

[an error occurred while processing this directive]